ACADIA Pharmaceuticals Inc.

NasdaqGS:ACAD 주식 리포트

시가총액: US$5.1b

ACADIA Pharmaceuticals 배당 및 자사주 매입

배당 기준 점검 0/6

ACADIA Pharmaceuticals 배당금을 지급한 기록이 없습니다.

핵심 정보

n/a

배당 수익률

-0.9%

자사주 매입 수익률

총 주주 수익률-0.9%
미래 배당 수익률0%
배당 성장률n/a
다음 배당 지급일n/a
배당락일n/a
주당 배당금n/a
배당 성향n/a

최근 배당 및 자사주 매입 업데이트

업데이트 없음

Recent updates

내러티브 업데이트 • Aug 19

ACAD: RADIANT Phase 2 Alzheimer’s Psychosis Data Will Drive Upside Potential

Analysts have increased their average price targets for ACADIA Pharmaceuticals by a few dollars per share, with higher fair value estimates at $47.18 that reflect increased confidence in remlifanserin and Daybue following recent research updates. Analyst Commentary Recent research coverage on ACADIA Pharmaceuticals points to a broadly constructive stance from bullish analysts, with a series of upward price target revisions clustered around key catalysts for Daybue and remlifanserin.
분석 기사 • Aug 08

Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) just released its quarterly report and things are looking bullish. It was...
내러티브 업데이트 • Aug 05

ACAD: Future Upside Will Hinge On Alzheimer Psychosis Remlifanserin Data

ACADIA Pharmaceuticals' analyst fair value estimate has been adjusted to $33.25 from $31.80 as analysts factor in stronger Daybue traction, higher long term profit margin assumptions, and the upcoming Phase 2 remlifanserin readout as key supports for higher price targets across the Street. Analyst Commentary Recent research on ACADIA Pharmaceuticals points to a generally constructive tone, with many firms lifting price targets and focusing on execution around Daybue, Nuplazid and the upcoming remlifanserin data.
Seeking Alpha • Jul 27

Acadia Pharmaceuticals: Why I'm Bullish Ahead Of The RADIANT Readout

Summary Acadia Pharmaceuticals Inc. ended July on a high note. The top line results from the Phase 2 RADIANT study of remlifanserin in Alzheimer’s disease psychosis are expected in August-October 2026. Acadia expects its 2026 revenue will be $1.22-$1.28 billion, representing about 16.5% YoY growth. Meanwhile, the average price target for Acadia is $32.8 [from $17 to $45], which implies an upside of about 32.1% from its current stock price. As a result, in my view, Acadia's risk/reward is attractive. Read the full article on Seeking Alpha
내러티브 업데이트 • Jul 22

ACAD: Alzheimer’s Psychosis Data Will Test High-Risk Remlifanserin Story

Analysts have raised their average price targets on ACADIA Pharmaceuticals by a few dollars per share into the mid $30s, citing expectations for stronger Daybue and Nuplazid trends, as well as updated views on pipeline assets such as remlifanserin and trofinetide, following recent positive CHMP opinions and study designs. Analyst Commentary Recent research on ACADIA Pharmaceuticals points to a mix of optimism around product momentum and caution around execution and drug development risk.
내러티브 업데이트 • Jun 17

ACAD: Buy Upgrade And Guidance Reaffirmation Will Drive Upside From Pullback

ACADIA Pharmaceuticals' analyst price target has been trimmed by $1, as analysts recalibrate their models around slightly different long term growth, profitability, and discount rate assumptions reflected in recent research updates. Analyst Commentary Recent Street research around ACADIA Pharmaceuticals shows a mix of caution and optimism, with the modest price target trim sitting alongside more constructive views from bullish analysts who see room for the stock to recover from recent weakness.
내러티브 업데이트 • Jun 02

ACAD: Rett And Alzheimer’s Psychosis Milestones Will Shape Balanced Risk Reward

Analysts have nudged their price expectations for ACADIA Pharmaceuticals higher, with the updated fair value estimate moving from about $19.64 to $19.75 per share as they refine assumptions around growth, margins, and future P/E multiples following recent target changes and rating updates on the stock. Analyst Commentary Recent Street research on ACADIA Pharmaceuticals reflects a mix of optimism and caution, with some firms lifting price targets and others trimming expectations or flagging risks.
내러티브 업데이트 • May 09

ACAD: Remlifanserin Alzheimer’s Psychosis Readout Will Drive Upside From Undervalued Levels

Analysts recently adjusted their fair value estimate for ACADIA Pharmaceuticals slightly lower to $43.55 from $43.97, reflecting updated assumptions for revenue growth, profitability, and future P/E. This revision also incorporates mixed but generally constructive Street price target updates in the $26 to $37 range, along with several fresh Buy and Outperform ratings.
내러티브 업데이트 • Apr 23

ACAD: Execution Risk Around Rett Syndrome Setback Will Limit Future Upside

Analysts trimmed the fair value estimate for ACADIA Pharmaceuticals slightly to $19.64 from $19.73, as modestly higher discount rate assumptions offset slightly stronger projected revenue growth and profitability. They maintained a supportive stance following a mix of recent price target increases and reductions across the Street.
내러티브 업데이트 • Apr 08

ACAD: Future Upside Will Depend On Alzheimer Psychosis Trial Outcomes

The fair value estimate for ACADIA Pharmaceuticals has increased slightly to $31.80, as analysts incorporate updated revenue growth assumptions, mixed adjustments to price targets across firms, and ongoing expectations for contributions from Nuplazid, Daybue, and the broader pipeline. Analyst Commentary Recent research coverage on ACADIA Pharmaceuticals shows a mix of optimism and caution, with several firms revising price targets after earnings updates, guidance, and pipeline commentary.
내러티브 업데이트 • Mar 24

ACAD: Remlifanserin Alzheimer’s Psychosis Data Will Drive Upside From Undervalued Levels

ACADIA Pharmaceuticals' updated analyst price target moves from $37 to about $44, with analysts pointing to refreshed models that reflect recent guidance, ongoing commercial momentum in Nuplazid and Daybue, and growing attention on the remlifanserin Phase 2 program in Alzheimer's disease psychosis. Analyst Commentary Recent Street research around ACADIA Pharmaceuticals clusters around refreshed models, updated sales assumptions for Nuplazid and Daybue, and rising interest in the remlifanserin program in Alzheimer's disease psychosis.
내러티브 업데이트 • Mar 10

ACAD: Trofinetide EU Setback And Execution Risks Will Likely Restrain Upside

ACADIA Pharmaceuticals' updated analyst price target reflects a modest reset in fair value to $19.73 from $20.26, as analysts balance recent target revisions across the Street with refreshed assumptions for growth, margins, and future P/E levels. Analyst Commentary Across recent research updates, views on ACADIA are mixed, with several large firms expressing confidence in the commercial trajectory of Nuplazid and Daybue, while others are more measured and focused on execution risks and how much of the current pipeline is already reflected in the share price.
내러티브 업데이트 • Feb 23

ACAD: Pipeline And Execution Risks Will Likely Cap Upside Despite Renewed Optimism

ACADIA Pharmaceuticals' updated fair value estimate has edged up from $19.65 to $20.26 per share, reflecting analysts' higher price targets tied to confidence in Nuplazid and Daybue, as well as underappreciated upside from the remlifanserin pipeline asset. Analyst Commentary Recent research views on ACADIA are mixed, with some firms pointing to upside tied to Nuplazid, Daybue, and the remlifanserin program, while others are more guarded.
내러티브 업데이트 • Feb 09

ACAD: Higher P/E Assumptions Will Rely On Successful Rett Syndrome Expansion

Analysts have nudged their fair value estimate for ACADIA Pharmaceuticals higher by about $0.47 per share, reflecting recent price target revisions and updated assumptions around revenue growth, profitability, and future P/E multiples. Analyst Commentary Recent Street research on ACADIA Pharmaceuticals has been active, with multiple firms revising price targets and updating their views on the company.
내러티브 업데이트 • Jan 25

ACAD: Execution Risk And Sector Capital Pressures Will Likely Constrain Upside

Narrative Update Analysts have lifted their price target on ACADIA Pharmaceuticals to US$40 from US$35, citing updated assumptions around revenue growth, profitability and future P/E expectations, alongside a generally cautious but constructive view on Biotech, with potential M&A activity helping to support the sector. Analyst Commentary While the updated US$40 target signals constructive sentiment on ACADIA Pharmaceuticals, recent commentary still carries a cautious tone around how the story plays out over time.
내러티브 업데이트 • Jan 11

ACAD: Higher P/E Assumptions Will Support Upside If Pipeline Milestones Deliver

Narrative Update Analysts have lifted their price target on ACADIA Pharmaceuticals to US$40 from US$35, citing a refreshed view on fair value, updated discount rate assumptions, and adjusted expectations for revenue growth, profit margin, and future P/E multiples. Analyst Commentary Recent commentary around ACADIA Pharmaceuticals reflects a mix of optimism on potential value creation and caution around sector level capital trends.
내러티브 업데이트 • Dec 26

ACAD: Expanded Neuroscience Pipeline Will Drive Upside From Undervalued Levels

Analysts have modestly increased their price target on ACADIA Pharmaceuticals from 35.00 dollars to 37.00 dollars. They cited slightly stronger long term revenue growth, improved profit margin expectations, a marginally lower discount rate, and a higher projected future price to earnings multiple.
내러티브 업데이트 • Dec 12

ACAD: Upcoming Neuropsychiatric Data Expected To Drive Upside Despite Recent Setback

Analysts have trimmed their price target on ACADIA Pharmaceuticals by $5 to $35 per share. This reflects a modestly higher discount rate and lower long term profit expectations, despite slightly stronger projected revenue growth and reassurance that the ACP-101 failure has only a small impact on overall valuation.
분석 기사 • Nov 13

Shareholders Shouldn’t Be Too Comfortable With ACADIA Pharmaceuticals' (NASDAQ:ACAD) Strong Earnings

Even though ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) posted strong earnings recently, the stock hasn't reacted in a...
분석 기사 • Nov 09

ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) came out with its quarterly results last week, and we wanted to see how the...
내러티브 업데이트 • Sep 26

Global Outreach And Pipeline Programs Will Expand CNS Markets

ACADIA Pharmaceuticals’ consensus price target was revised downward to $29.32 as the Phase 3 failure of ACP-101 in Prader-Willi syndrome modestly reduced pipeline value, though the impact is seen as limited given low expectations and resilience in the core business. Analyst Commentary Bearish analysts cite the Phase 3 failure of ACP-101 in Prader-Willi syndrome (PWS), which missed its primary endpoint, leading to lowered price targets based on reduced near-term pipeline value.
내러티브 업데이트 • Sep 04

Global Outreach And Pipeline Programs Will Expand CNS Markets

Analysts maintained their price target for ACADIA Pharmaceuticals at $29.95 as strong Daybue growth, favorable Nuplazid patent rulings, and strategic R&D focus offset near-term competitive and pipeline uncertainties. Analyst Commentary Bullish analysts are raising price targets citing strong Daybue growth in Q2, but note further acceleration is needed for material upside.
Seeking Alpha • Feb 13

Acadia Pharmaceuticals: Good Progress Means I'm Reversing My 'Sell' Call To 'Buy'

Summary Acadia Pharmaceuticals has shown significant financial improvement, reporting a profit of $82.7m in 2024, compared to a loss of $(107m) in 2023. The company's revenue growth is driven by NUPLAZID and DAYBUE, with 2024 revenue projections of $600m-$610m and $340m-$350m respectively, and overall revenues forecast to exceed $1bn in '25. Acadia's promising pipeline, including ACP-204 and ACP-101, and successful marketing campaigns suggest strong future growth potential. Given the company's profitability, robust pipeline, and undervaluation compared to peers, I am upgrading Acadia from "Sell" to "Buy". Read the full article on Seeking Alpha
Seeking Alpha • Nov 27

Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET

Summary NUPLAZID and DAYBUE are each delivering double-digit percentage net product sales growth. Company is on track to reach more than $1 billion in annualized net product sales in 2025. Next phase of growth could come from two late-stage assets known as ACP-101 for hyperphagia of PWS and ACP-204 for Alzheimer's Disease Psychosis. Company entered into a worldwide license agreement with Saniona to develop and commercialize SAN711 for the treatment of patients with Essential Tremor; Phase 2 study to be initiated in 2026. Read the full article on Seeking Alpha
Seeking Alpha • Nov 11

Acadia Pharmaceuticals: Proving The Naysayers Wrong

Summary Today, we are revisiting with mid-cap biopharma Acadia Pharmaceuticals Inc., whose stock surged some 20% last week following Q3 results. The company beat both top and bottom-line expectations and also posted updated FY2024 guidance. Acadia Pharmaceuticals is becoming profitable, has a pristine balance sheet, and is seeing solid growth. An updated analysis around ACAD stock follows in the paragraphs below. Read the full article on Seeking Alpha

지급의 안정성과 성장

배당 데이터 가져오는 중

안정적인 배당: 과거에 ACAD 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: ACAD 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

배당 수익률 vs 시장

ACADIA Pharmaceuticals 배당 수익률 vs 시장
ACAD의 배당 수익률은 시장과 어떻게 비교되나요?
구분배당 수익률
회사 (ACAD)n/a
시장 하위 25% (US)1.3%
시장 상위 25% (US)4.0%
업계 평균 (Biotechs)1.8%
분석가 예측 (ACAD) (최대 3년)0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ACAD 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ACAD 의 배당 수익률을 평가할 수 없습니다.

주주 대상 이익 배당

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ACAD 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주 현금 배당

현금 흐름 범위: ACAD 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

높은 배당을 제공하는 우량 기업 찾기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/08/22 18:16
종가2026/08/21 00:00
수익2026/06/30
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

ACADIA Pharmaceuticals Inc.는 38명의 분석가가 다루고 있습니다. 이 중 20명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
null nullBaird
Jack AllenBaird
Joel BeattyBaird